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Lentiviruses have unusually long envelope (Env) cytoplasmic tails, longer than those of other retroviruses. Whereas
the Env ectodomain has received much attention, the gp41 cytoplasmic tail (gp41-CT) is one of the least studied
parts of the virus. It displays relatively high conservation compared to the rest of Env. It has been long established
that the gp41-CT interacts with the Gag precursor protein to ensure Env incorporation into the virion. The gp41-CT
contains distinct motifs and domains that mediate both intensive Env intracellular trafficking and interactions with
numerous cellular and viral proteins, optimizing viral infectivity. Although they are not fully understood, a
multiplicity of interactions between the gp41-CT and cellular factors have been described over the last decade;
these interactions illustrate how Env expression and incorporation into virions is a finely tuned process that has
evolved to best exploit the host system with minimized genetic information. This review addresses the structure
and topology of the gp41-CT of lentiviruses (mainly HIV and SIV), their domains and believed functions. It also
considers the cellular and viral proteins that have been described to interact with the gp41-CT, with a particular
focus on subtype-related polymorphisms.
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Background: Env and the entry process
The main target cells for the Human Immunodeficiency
Virus type 1 (HIV) and Simian Immunodeficiency Virus
(SIV) are CD4-expressing cells, namely CD4+ T lympho-
cytes, dendritic cells (DCs) and macrophages. The first step
of the viral cycle, involving anchoring to the target cell
membrane and entry, is mediated by the envelope glyco-
protein (Env). Env is composed of two non-covalently
linked subunits, SU (surface glycoprotein or gp120) and
TM (transmembrane glycoprotein or gp41), displayed as
heterotrimeric spikes on the surface of virions and infected
cells [1-6]. The two Env subunits are the products of the
proteolytic cleavage of a highly glycosylated gp160 precur-
sor protein by the cellular protease Furin in the Golgi ap-
paratus. gp120 is responsible for binding to the CD4
receptor and the coreceptor expressed at the cell surface of
target cells. gp120 is composed of several variable and con-
stant regions; it comprises a heavily glycosylated outer* Correspondence: danielle.perezbercoff@crp-sante.lu
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distribution, and reproduction in any mediumdomain and an inner domain, which are linked by a struc-
ture called the bridging sheet. Mature Env thus forms a
cage-like structure with an interior void; this cage-like
structure is believed to restrict antibody access [7]. gp41 is
non-covalently linked to gp120 and the N-terminal
ectodomain of gp41 contains a hydrophobic, glycine-rich
fusion peptide that mediates fusion of the viral and target
cell membranes. Binding of gp120 to the CD4 receptor in-
duces conformational changes that expose the third hyper-
variable region (V3 loop) of gp120, which in turn binds
one of the co-receptors, CCR5 or CXCR4 [8-12]. Binding
to the co-receptor triggers further conformational changes
within gp41, which adopts the so-called “fusion-active”
state required for bringing the viral and cellular mem-
branes into close contact and allowing fusion. These con-
formational changes involve two leucine zipper-like motifs,
the heptad repeat 1 (HR1) and heptad repeat 2 (HR2): HR2
folds in an anti-parallel fashion onto the pre-formed trimer
of HR1 helices, allowing HR1 and HR2 to assemble into a
highly stable antiparallel six-helix bundle structure, which
juxtaposes the viral and cellular membranes, and allows fu-
sion of the viral and cellular membranes [2,3,5,6,13].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mic reticulum (ER) or the cis-Golgi compartments and
only a small proportion progresses through the trans-
Golgi network (TGN) and reaches the cell membrane
[14-17]. As it is synthesized and oligomerizes in the rough
ER (RER), Env is extensively N-and O-glycosylated, sul-
fated and plamitoylated concomitantly with its translation
and transit through the TGN [1,18-24] reviewed in [25].
Glycosylation of gp120 accounts for nearly half of its
molecular mass. This substantial glycosylation is believed
to ensure correct protein folding and to favor immune
escape by providing a glycan shield against neutralizing
antibodies. As the disease progresses, viral strains lose po-
tential N-glycosylation sites (PNGs) and display notably
reduced glycosylation; these strains are consequently less
well shielded from neutralizing antibodies [26,27]. None-
theless, such viral strains appear late during infection, con-
comitantly with the decline in CD4+ T cell counts, such
that the immune system is unable to trigger an efficient B-
cell response; consequently, evading the immune system is
no longer necessary [28].
Env is the most variable region of the HIV genome, and
inter-subtype diversity is typically up to 25-35%. This vari-
ability is not evenly distributed throughout the env gene:
the gp120 ectodomain is the most variable, the gp41
ectodomain is the least variable, and the gp41 cytoplasmic
tail (gp41-CT) lies somewhere in between, with an inter-
mediate level of sequence diversity and phylogenetic evolu-
tion [29]. Experimental data obtained from peptides and by
sequence analysis and modeling indicate that the structural
and physicochemical properties of the gp41-CT are sur-
prisingly highly conserved despite the sequence variations.
Presumably, this reflects constraints on its evolution im-
posed by crucial functional roles. However, these roles have
mostly been explored using the NL4-3 reference strain or
synthetic peptides.
Aims of the review
The ectodomain of Env has been the subject of much
interest and substantial investigations. The structural
and functional characterization of the HIV and SIV
gp41-CTs has received far less attention, and indeed,
there are numerous contradictory results. Early studies
of the gp41-CT mainly addressed the immunogenic
properties of the Kennedy epitope, or the viroporin
properties of the α-helical lentiviral lytic peptides LLP-
1, LLP-2 and LLP-3 and their role in viral incorporation
and infectivity. The discovery that the gp41-CT inter-
acts with the p55Gag precursor during viral assembly
and ensures Env incorporation into virions has led to a
reconsideration of the functional importance of this do-
main. It was, nevertheless, only very recently that its role
in modulating Env expression and viral infectivity through
a plethora of interactions with cellular partners started tobe appreciated. Three recent reviews are relevant: they ad-
dress the role of the HIV-1 gp41-CT in Env trafficking, in-
corporation and viral assembly [25], the biophysical
properties and topology of the gp41-CT [30] and the inter-
actions of the gp41-CT with cellular factors [31]. Parallel
spectacular advances in cell and virion imagery, and very
recent studies on the biophysical characteristics of mature
and immature virions based on Atomic Force Microscopy
(AFM) [32] and STED microscopy [33] provide new in-
sights into the contribution of the gp41-CT to viral fusion
efficiency. Here, we review current knowledge on the gp41-
CT and its believed structure and function as a regulator of
viral infectivity. In particular, we focus on variability and
subtype-related specificities, as most studies on the gp41-
CT are based on the NL4-3 reference and mutants thereof,
in sharp contrast to studies on the Env ectodomain.
Structural determinants and topology of the gp41-CT
Structure of the gp41-CT
The gp41-CT of lentiviruses is unusually long (~150 amino
acids) and substantially longer than the tails of other retro-
viruses (< 50 AA) [34] (Figure 1A). Although amino acid
(AA) sequence identity is not conserved, both secondary
structures and various endocytic and trafficking motifs are
highly conserved across HIV-1 clades and even among len-
tiviruses in general [29,30] (Figure 1B). Immediately down-
stream from the membrane-spanning domain, gp41-CT
has a loop containing the highly immunogenic Kennedy
epitope (KE) which is not believed to adopt any particular
conformation. The KE in fact harbors three consecutive
epitopes (P728DRPEG732, I733EEE736 and E739RDRD743)
[35]. Antibodies against the KE (SR1) display neutralizing
activity against the infectivity of free virus and impair cell-
to-cell spread by inhibiting Env-mediated fusion [36-38].
ERDRD is a conformational epitope and elicits production
of neutralizing antibodies; the linear IEEE epitope seems to
deflect the humoral response to favor viral immune escape
from a neutralizing response against ERDRD [35].
The KE is followed by three α-helical motifs named
lentiviral lytic peptides (LLP)-2 (AA 768 to 793 of NL4-3),
LLP-3 (AA 785 to 807) and LLP-1 (AA 828 to 856) [39-41]
(Figure 1B). LLP-3 partly overlaps LLP-2, and has been less
studied than the other two LLP domains. Biochemical ana-
lyses with LLP peptides indicate that although primary
amino acid identity is not conserved across clades (with
the exception of the more conserved LLP-1), these do-
mains adopt an α-helical structure in a membrane-mimetic
environments and random coil conformations in an aque-
ous environment [29,30]. Early studies focused on deter-
mining the role and biochemical properties of these
domains; they were based on synthetic peptides and three-
dimensional computer modeling [39,40,42] or point muta-
tions and truncation mutants of the gp41-CT, analyzing
Env incorporation into virions [43-46] (detailed below),
Figure 1 Lengths of the cytoplasmic tails of various retroviruses and sequence alignment of different HIV-1 subtypes, clades and
types. (A) Comparison of the lengths of the gp41-CT of Human Immunodeficiency Virus type 1 (HIV-1), HIV type 2 (HIV-2), Simian
Immunodeficiency Virus (SIV), Feline Immunodeficiency Virus (FIV), Equine Infectious Anemia Virus (EIAV), Maedi-Visna Virus (MVV), Caprine Arthritis
Encephalitis Virus (CAEV), Human T-lymphotropic Virus type I (HTLV-1), Human T-lymphotropic Vtype 2 (HTLV-2), Mouse Mammary Tumor Virus
(MMTV), Murine Leukemia Virus (MLV) and Gibbon Ape Leukemia Virus (GaLV); conserved YxxФ motifs (where Ф represents a hydrophobic
residue) are highlighted. (B) Sequence alignment of the gp41-CT from various lenviviral (HIV and SIV) types and subtypes: HIV-1 subtypes A
(92UG037), B (HXB2), C (ETH2220), D (SE365), F1 (93BR020), G (175), H (90CF056), CRF02_AG (93TH065), clade O (ANT70) and clade N (YBF106),
HIV-2 (UC2), SIVcpz (Ptt_04CAM155) and SIVsmm (H635). AA positions are aligned against the NL-3 reference used in most studies of the gp41-CT.
Lentiviral lytic peptide (LLP) domains, Kennedy epitopes and antibodies directed against them are shown. Conserved YxxФ motifs are highlighted
in orange; conserved dileucine motifs, and motifs involved in cell trafficking are highlighted in green.
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tide form, the LLP domains interact with the plasma mem-
brane [41,48,49] and thereby decrease bilayer stability
[41,50] or alter the ionic permeability of membranes
[48,50,51]. Intracellular localization studies suggested that
the LLP helices may lie adjacent to and line the plasma
membrane [49] (Figure 2A). These observations have led to
the idea that the LLP domains are involved in fusogenicity,
immunogenicity, and in conformational regulation of Env
accompanying viral maturation and infectivity (see below,
section ‘Viral stiffness, viral maturation and infectivity’).
Functional domains of the gp41-CT
Mutational analyses and work with truncation mutants of
specific LLP-1 or LLP2 domains indicate varying Env ex-
pression and processing phenotypes, depending on the ex-
tent of the truncation and on the cell type. Despite subtle
differences in the extent of the truncations studied, it ap-
pears that deleting the C-terminal domain of LLP-1 dimin-
ishes virion infectivity and cell-to-cell spread, due to
decreased Env incorporation into virions [43-46,52] and to
diminished Env expression and stability of the gp41/gp120
heterodimeric complex both at the cell membrane and in
virions [44,53]. Env protein synthesis and processing in
transfected HeLa or HEK293 cells is however unaffected by
truncations of the C-terminal domain of LLP-1 [43,46,53].
Larger truncations, i.e. truncation of the full gp41-CT, or
the region downstream from LLP-3 (i.e. deleting upstream
from LLP-1), or even LLP-1 deletions or point mutations in
this region dictate Env fusion capacity of mature [46] and
immature virions [47,54]. Some authors attributed this
phenotype to failed Env multimerization, a prerequisite for
viral infectivity [55,56]; others proposed that truncation of
LLP-1 induces modifications of the helical structure of
LLP-2 and/or alterations in the structure of the EnvFigure 2 Schematic representation of the topology of the gp41-CT. A
membrane-spanning domain (MSD) is an α-helix (boxed). B. Alternative model
β-sheets (arrows) and the KE is exposed extracellularly. Adapted from Steckbec
“carrier” peptide and may interact with the HR1-HR2 6-helix bundle at the mom
membrane. Adapted from Lu et al. J Biol Chem 2008 [60].ectodomain, suggesting an inside-out regulation of viral in-
fectivity and fusion capacity [46,47,54,57,58]. Biochemical
studies involving the use of synthetic peptides found that
viral infectivity is dependent on interactions of LLP-1 and
LLP-2 with the cell membrane [49,56,58] and/or with re-
gions of the gp41 ectodomain, and particularly the HR1-
HR2 6-helix bundle [29,59,60]. For SIVmac239, truncations
of the gp41-CT affected the fusion capacity of Env in HeLa-
CD4 cells by changing the conformation of the Env gp41
ectodomain [61] or the amount of gp120 on the surface of
the virion due to an unstable gp120-gp41 association [62].
Indirect support for gp41-CT affecting the conformation of
the gp41 ectodomain has been provided by studies showing
that truncations of the gp41-CT affect the conformation of
gp120 [57] and of the gp41 ectodomain [63]; also, such
truncations interfere with the accessibility of these domains
to antibodies targeting various epitopes including the CD4
or co-receptor binding sites [57] or the Membrane Prox-
imal External Region (MPER) (neutralizing antibodies such
as 2F5 and 4E10) [63]. In addition, a L49D mutation in the
matrix protein (MA) of the p55Gag precursor, which inter-
acts with the gp41-CT (see below, section ‘Viral assembly,
Env incorporation into virions and viral infectivity’), is asso-
ciated with decreased amounts of gp120 at the surface of
the virion without affecting gp41 incorporation [64]. This
suggests that modifications to the MA/gp41-CT interaction
may affect the level of gp120 incorporation [64]. This defect
could be reversed by truncating the gp41-CT or disrupting
the Y712SPL endocytic motif (i.e. impairing Env down-
regulation, see section ‘Env trafficking and sorting through
the TGN’). This implies that altering the interaction be-
tween p55Gag and the gp41-CT affects the conformation of
gp41 and thereby the incorporation of gp120 into virions
[64]. Although these reports are descriptive and the pro-
posed mechanisms are divergent, these studies agree that. Conventional model, in which gp41 spans the membrane once and the
in which the gp41-CT crosses the membrane three times via antiparallel
k et al. PlosOne 2010 [71]. C. LLP-2 is a membrane-traversing peptide or a
ent of fusion. In this conformation, the KE would also traverse the plasma
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ectodomain [46,47,54,57,58] and the stability of the 6-helix
bundle [29,59,60] thereby affecting fusion capacity and sen-
sitivity to neutralization [57,63].
The dileucine motifs that span the gp41-CT LLP
helices play a role in viral replication, as has been
demonstrated through a cumulative mutagenesis ap-
proach [65]. Bhakta et al. reported a cumulative effect
on the infectivity of free virions and on viral propaga-
tion that did not correlate with modifications in viral
incorporation or expression at the cell membrane [65].
Importantly, disruption of individual dileucine motifs
had only a moderate impact, whereas the cumulative
effect was substantial, suggesting a degree of flexibility,
and tolerance of mutations of single dileucine motifs
[65]. This study reconciles early and more recent
reports on the role of the gp41-CT, as it suggests that
impaired replicative capacity and viral spread may re-
sult from disrupting the hydrophobic properties of the
LLP-2 α-helix: this disruption may impair interactions
with the cell membrane and/or membrane transloca-
tion and interaction with the HR1-HR2 6-helix bundle
[65]. Another possible explanation is that altering the
biochemical amphipathic properties of the gp41-CT,
or simply disrupting the LL dileucine domains, inter-
feres with Env/Env interactions and coalescence
[33,55], thereby affecting infectivity. This issue re-
quires further investigation. Intriguingly, a highly con-
served seven AA insertion (NSLKGLR) between R787
and R788 (LLP-2 domain) is found in many subtype C
strains where the dileucine motifs spanning the gp41-
CT are disrupted (ESS, MM and DPB, unpublished ob-
servation). The two supplementary α-helical turns re-
sult in three arginine residues being aligned side-by-side
on the hydrophilic face of the α-helix. Whether adding
these two α-helical turns to LLP-2 modifies its biophysical
properties remains to be established.
The gp41-CT also harbors many functional determinants,
including internalization motifs, for example: two YxxΦ
motifs (Φ representing a hydrophobic AA, generally L in
HIV and V in SIV), one immediately downstream from the
transmembrane domain (membrane-proximal YxxΦ) and
one within LLP-2; a Y802W803 diaromatic motif within LLP-
3; two inhibitory sequences named IS1 (AA 750 to 763 of
HXB2) and IS2 (AA 764 to 785); and the various dileucine
(LL) motifs spanning the gp41-CT (Figure 1B). The role of
these motifs in Env trafficking and protein-protein interac-
tions is considered in more detail below (section ‘Interac-
tions of the gp41-CT with cellular factors and intracellular
regulators’).
Topology of the gp41-CT
gp41 is generally thought to be a type I membrane-
spanning protein, with one α-helical membrane spanningdomain (MSD) (AA 671–705) [66]. However, alternative
models have been proposed, in which the gp41-CT lies
partly outside the virus or the infected cell, crossing the
membrane three times [38,60,67-71] (Figure 2B and C).
The Kennedy Epitope
Serum from HIV-infected individuals contains anti-
bodies against epitopes within the KE. This has led to
the hypothesis that this region is exposed extravirally
and extracellularly, consistent with gp41 spanning the
membrane three times rather than once [38,67-70]. In
this model, the membrane-spanning domains form
three antiparallel β-sheets [30,71] (Figure 2B). In sup-
port of this model, IgG against the gp41-CT-encoded
epitopes P728DRPEG732, I733EEE736 and E739RDRD743
bound and neutralized free virions, and protease diges-
tion inhibited antibody binding [69]. Other studies
showed that neutralization by these antibodies extended
to cell-to-cell fusion [38]. However, this model places the
Y712SPL internalization motif outside the cell such that it
would not allow and ensure an interaction of Env with cel-
lular partners (see section ‘Env trafficking and sorting
through the TGN’). Moreover, experiments per-
formed with amphotericin B methyl ester (AME), a
cholesterol-binding compound that interferes with
virion-cell membrane fusion, showed that AME-
resistant HIV variants contained mutations within the
gp41-CT that create a cleavage site for the viral
protease within the Y712SPL motif [72]. By cleaving
the gp41-CT, HIV mimics the shorter gp41-CT of
other retroviruses to restore Env fusogenicity [72,73].
(In the case of SIV, AME-resistant SIV gp41-CT
displayed a premature STOP codon [72], and the topology
of the gp41-CT does not affect its capacity to arise). Cleav-
age of the gp41-CT by the viral protease is not compatible
with this epitope lying outside the virion. A more dynamic
view of gp41-CT topology has recently been proposed to
reconcile these observations [71] (reviewed in [30]). This
model posits that the KE can adopt various distinct top-
ologies: inside the virion, the KE would lie intravirally
(Figure 2A), whereas in transfected/infected cells, the KE
would lie outside the cell (Figure 2B) [71]. In support of
this model, the authors present evidence that the gp41-CT
of all HIV clades and of SIV share a highly conserved
enrichment in arginine over lysine [29,40]. Arginine-rich
peptides may be located within lipid environments and
may readily cross biological membranes due to their
guanidium group; they can also carry soluble proteins
across membranes [74-77]. This dynamic model is com-
patible with the viral protease cleaving the gp41-CT in the
virion under AME selective pressure. Note, however, that
the authors compared the location of the KE in virions
(i.e. in entities containing MA) with that in cells
transfected with a construct encoding Env only rather
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The interaction between the gp41-CT and p55Gag (see sec-
tion ‘Interaction of the gp41-CT with Gag’) is not taken
into account in this model and it may not be excluded that
the absence of Gag in the experimental setup may bias the
topology of the gp41-CT, including that of the KE.
The dynamic topology model still predicts that the
Y712SPL internalization motif is outside the cell: this is
not consistent with the regulation of Env expression at
the plasma membrane of infected cells through adaptor
protein (AP)-mediated internalization (see section ‘Env
trafficking and sorting through the TGN’). The authors
[71] do not address this point. This dynamic model has
been opposed on the grounds that the model for a
dynamic intra/extra viral localization of the KE is based
solely on indirect observations, and in particular labeling
with antibodies raised against this epitope [78]. In a very
recent study based on the SIV gp41, it was convincingly
shown that the reported surface labeling was due to the
release of Env from expressing cells into the supernatant;
shed Env subsequently attaches to the surface of cells in
the culture [78]. The authors report that transferring
supernatant from Env-transfected cells to mock-transfected
cells was sufficient for labeling of the mock-transfected cells.
Furthermore, the PNG in the KE was never glycosylated,
and both serum and monoclonal antibodies against the KE
failed to neutralize even highly neutralization-sensitive
strains [78].
LLP-2
Biochemical studies led to the suggestion that LLP-2
may also be a traversing peptide, and that it interacts
with the extracellular 6-helix bundle at the moment of
fusion [60] (Figure 2C). LLP-2 exposure may be induced
by CD4 and CCR5 binding, and be highly transient, as
implied by the observations that antibody binding is ob-
served at 31.5°C but not at 37°C and that LLP-2 peptides
bind peptides mimicking the 6-helix bundle in biochem-
ical experiments [60]. The mechanisms underlying this
crossing of the membrane are unclear; the exact extent of
membrane crossing by LLP-2 has not been investigated,
so this remains speculative. As this study was based on a
biochemical approach using peptides and antibody bind-
ing, the possibility of a biased interpretation due to label-
ing of shed Env subsequently bound to the cell surface, as
described by Postler et al. for KE epitopes [79], cannot be
excluded. Furthermore, the absence of other viral proteins
from the Env-transfected cell system pleads for caution in
interpreting the results, as indicated by the authors them-
selves [60]. Furthermore, Steckbeck et al. described the
introduction of known epitopes into LLP-2, and failed to
detect any extracellular or extraviral labeling, whereas
similar epitopes inserted within KE epitopes were success-
fully detected [71].These diverse results are such that caution is still
required for any conclusions concerning a cell-versus-virion
conformation of Env. It remains unclear whether there are
such transient rearrangements and biochemical adjust-
ments of Env in response to modifications in the mem-
brane lipid or protein environment during viral assembly or
at the moment of fusion; the corresponding observations
may be experimental artifacts that do not reflect to
biological realities. No images are available of the conform-
ation and distribution of Env gp41-CT in the immature
forming virion or in the mature virion. If the gp41-CT does
adopt different topologies and if both the KE and LLP-2 are
indeed membrane-traversing peptides, it would be interest-
ing to investigate whether both can be found extracellularly
at the same time, or whether such a conformation would
be too highly unfavorable.
Open questions
A series of questions remain unanswered. For example,
why is there such strong constraint on the structure of the
LLP peptides but not on their sequences? How does this
structure favor infectivity, motility or clustering of the Env
in the virion? Does the conformation of the gp41-CT
change upon virion maturation p55Gag cleavage by the viral
protease? Does the gp41-CT really adopt different topolo-
gies? If so, what triggers the switch from an intraviral/intra-
cellular to extraviral/extracellular localization of KE or of
LLP-2, and how are the KE and LLP-2 retained intravirally
or “freed”? And what would the function of transiently ex-
posing the highly immunogenic KE be? Alternatively, if the
immune response elicited by the KE is due to Env shedding
rather than to extracellular exposure, could this be a viral
strategy to evade the immune system, by providing
immunodominant domains that are subsequently not
accessible to antibodies as they are located inside the virion
and infected cells?
Viral assembly, Env incorporation into virions and viral
infectivity
Env is produced in the RER and the Golgi network, whereas
the p55Gag and p160GagPol protein precursors and the
accessory proteins are synthesized by cytosolic ribosomes.
Viral assembly thus requires viral components synthesized
in distinct cellular compartments and the genomic RNA to
come together and to interact at the budding interface. Viral
assembly is a highly regulated phenomenon, dictated by
intracellular trafficking.
HIV assembly and budding occurs at the plasma mem-
brane (PM) [80-84] in detergent-resistant-membrane lipid
raft-enriched domains [73,85-87] (Figure 3). The p55Gag
precursor is a polyprotein, including the structural pro-
teins of HIV, namely the matrix protein (MA) lining the
cell-derived viral envelope, the capsid protein (CA), con-
stituting the viral cone-shaped capsid containing the viral
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the viral RNA genome, and p6, regulating the viral prote-
ase, as well as two spacer peptides, SP1 and SP2. MA
drives and regulates p55Gag targeting to the PM by
preferentially interacting with phosphatidylinositol 4,5
bisphosphate [PI(4,5)P2] [88-90]. Once it has reached the
PM, the p55Gag precursor is anchored by its N-terminal
myristoylated moiety [91,92] and stabilized by basic resi-
dues 84–88 [89,90,92]. The myristoylated moiety is co-
translationally coupled to the p55Gag MA domain, and its
exposure is regulated by binding to calmodulin: binding to
calmodulin induces conformational changes within MA
[93,94] which lead to p55Gag binding to lipid rafts [95-97],
where it oligomerises [73,86,87,98], through the C-ter-
minal domain of CA and the α-helical spacer peptide SP1,Cytosolic synthesis of 
p55Gag and  p160GagPol


































Figure 3 Schematic representation of the interacting partners of the
rough endothelial reticulum (RER), where it is glycosylated and oligomerize
formation of the gp120-gp41 structure. Once it reaches the plasma membr
motifs interacting with AP-1 and AP-2. Cycling through the trans Golgi net
TIP47, via the Y802W803 diaromatic domain, and with AP-1 via Y712SPL. Env
The p55Gag precursor is synthesized in the cytoplasm and accumulates at t
LLP-2) with the Matrix protein (MA) ensures Env incorporation into the bud
activation through phosphorylation of IκB is mediated by interaction of the
transcription is mediated by LLP-2. Abbreviations: RER: rough endoplasmic
lytic peptide; TAK: TFG-β-activating factor; AP: adaptor protein: TIP47: Tail-inleading to the formation of the immature lattice [99,100].
In solution, MA within the p55Gag precursor assembles in
trimers [101]. In cholesterol-rich membranes composed
of phosphatidylcholine, cholesterol and [PI(4,5)P2],
myristoylated MA assembles in hexamers of trimers
interconnecting the radially oriented immature p55Gag
lattice [99,102,103].
Four models of viral assembly and budding have been de-
scribed exhaustively in three recent reviews [25,104,105]
and will therefore not be addressed in detail again here.
Briefly, the “Passive incorporation model” posits that HIV
assembly occurs by random co-localization of p55Gag and
Env at the cell membrane; it is supported by the observa-
tions that a number of cellular membrane proteins are





















gp41-CT in the cell. The Env precursor gp160 is synthesized in the
s into trimers. Furin cleavage in the Golgi apparatus enables the
ane (PM), Env is subject to endocytosis, via the Y712SPL and L855L856
work and between endosomes is ensured through interactions with
is targeted to the PM through Y712SPL interaction with AP-1 and AP-3.
he PM in lipid raft-rich domains. Interaction of the gp41-CT (through
ding virion. gp41-CT interacts with Nef through L855L856. NF-κB
Y768 with TAK-1. Interference with luman-mediated inhibition of
reticulum; TGN: trans Golgi network; CaM: calmodulin; LLP: lentiviral
teracting protein 47 kDa; Ub: ubiquitin ; Phb: Prohibitin.
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and non-retroviral envelopes (e.g. alphaviruses, ortho/
paramixoviruses, flaviviruses, etc.) [106-109], and by the
fact that gp41-CT truncations do not affect Env incorpor-
ation in some cell types (e.g. the HeLa cell line) (reviewed
in [25,104]). The three other models, in contrast, propose
that p55Gag and Env are co-targeted to assembly platforms
in a highly regulated fashion, either through direct p55Gag/
Env interaction, or through an indirect interaction medi-
ated by lipid rafts, or by other cellular factors (for details,
see [25]). Indeed, several lines of evidence suggest that
p55Gag and the gp41-CT interact [52,110-118]. However,
whether the MA/gp41-CT interaction is direct or involves
other partners remains controversial and requires further
investigation: coimmunoprecipitation studies and cell-free
protein-protein interaction studies suggest a direct inter-
action between gp41-CT and p55Gag [112,113,116], but fur-
ther interactions involving cellular or other viral proteins,
such as adaptins AP-1 through AP-4 or TIP47, lipid rafts
themselves and other lipid raft components have also been
described. One possible explanation for this diversity of re-
ports is that the interacting partners may have stabilizing or
facilitating effects, that are not required at all moments, or
that are inessential in some cell types. The observation that
gp41-CT truncation alters the localization and affects
polarization of the viral capsid at the viral synapse (VS) in
some cell types (see section ‘Phenotypes of gp41-CT trun-
cations’) supports this view [119,120].
Interaction of the gp41-CT with Gag
In the absence of Env, Gag and viral-like particles (VLPs)
bud in a non-polarized manner from the epithelial cell
membrane suggesting the existence of a p55Gag/Env
interaction. Env drives p55Gag accumulation and virion
budding from the basolateral surface of polarized cells
(MDCK cells in early reports, then extended to all polar-
ized cells) [111,121,122]. This polarized release was
shown both to be mediated by the Y712SPL motif of the
gp41-CT and to require interaction between Env and
MA [111,121,122]. Likewise, truncation of the gp41-CT
of a SIV strain resulted in redistribution of cell surface
envelope molecules from localized patches to a diffuse pat-
tern that covered the entire plasma membrane [123]. Con-
versely, Env glycoproteins produced alone are randomly
scattered across the cell plasma membrane, whereas in the
presence of p55Gag they are recruited to budding sites,
suggesting active recruitment to these sites [109].
Further evidence that a Gag/Env interaction is required
for the process of viral assembly arises from the observa-
tion that although truncation of the entire gp41-CT gener-
ally has little or no effect on Env incorporation, and even
increases Env expression at the cell membrane, deletions
downstream of the KE (ablating the LLP domains) or small
deletions within LLP-2, severely hamper Env incorporation[43-46,52]. This defect can be reversed by mutations
(V34I) in MA [52]. Conversely, it was reported that muta-
tions in the p55Gag precursor MA protein result in
decreased plasma membrane expression of Env [110],
and in lower Env stability and virion incorporation
[110,119,124,125]. The discovery that mutations in MA
interfere with Env incorporation in ‘non-permissive’ cells
and that pseudotyping with shorter Envs (MLV or a trun-
cated HIV-2) or truncating the HIV-1 gp41-CT reversed
this impairment confirm that the gp41-CT interacts with
the p55Gag precursor [52,114,115,118]. Importantly, these
findings have led to the idea that the gp41-CT plays a role
in assembly during the late stages of the viral cycle, rather
than in Env fusogenicity and in entry during the early
stages of the replication cycle [52,114,118].
The MA/Env interaction has variously been mapped to
L12 and L30 within MA [52,114,118], to K32 [110], and
to the MA-CA junction [114-116,118]. The defect in Env
incorporation into virions containing the L12E mutation in
MA can be reversed by truncations of the gp41-CT depriv-
ing it of the LLP domains [114,115,118], and MA AA L30
has been shown to interact with the C-terminus of LLP-2
[52]. Other studies based on progressive HIV-1 or SIV
gp41-CT truncation mutants (67 AA, or a central peptide
of 93 AA) confirmed that this interaction mapped to LLP-2
[52,112,113,126]. Another group however repeatedly
mapped the interaction to the 28 C-terminal AA (i.e. to
LLP-1) [47,54,116]. Despite the diversity of truncations that
have been studied, the observation that removal of 59 to 90
AA from the gp41-CT strongly impairs Env incorporation
into virions whereas removing 93 AA from the C-terminus
does not affect Env incorporation [115,118] suggests that
LLP-2 does not adopt an appropriate conformation in the
absence of LLP-1, and fails to accommodate the p55Gag
precursor. Lastly, Env and MA sequences from patient-
derived viral strains co-evolved over time [127], providing
further ex vivo support for a gp41-CT/p55Gag interaction.
The gp41-CT/p55Gag interaction seems to tolerate a
degree of flexibility, as MA mutations that abolish
incorporation of HIV-1 Env do not interfere with the in-
corporation of heterologous retroviral Envs with short
CTs [115,118] and as HIV can be pseudotyped with a var-
iety of retroviral and non-retroviral Env glycoproteins
[106-109]. This contrasts with VSV cores, which cannot
be pseudotyped by HIV gp160 [128]. The Env/Env inter-
action mediated by the gp41-CT [33], in contrast, is highly
specific as recent studies mixing Env glycoproteins from
lentiviruses (HIV or SIV) and from two retroviruses (RSV
and MLV) to produce pseudovirions show that Env clus-
tering at the plasma membrane is dependent on the Env
gp41-CT and is limited to autologous Envs [106,109]; also
in another study, the formation of hybrid pseudovirions
was not tolerated, although in this case, the non-retroviral
Ebola Env glycoprotein and HIV were mixed [108].
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It is currently believed that the p55Gag precursor orches-
trates viral assembly through interactions with all viral com-
ponents to be incorporated, and that the gp41-CT/p55Gag
interaction is involved in controlling viral infectivity in a
maturation-dependent fashion. The efficiency of entry and
fusion is lower for immature than mature HIV-1 particles
[47,54,129]. Similar results have been reported for the SIV
Env-CT [117]. This inefficiency can be overcome by trunca-
tion of the gp41-CT or by LLP-1 truncations [47,54,114].
It has been proposed that the plasticity of the lentiviral
particle controls its infectivity and fusion capacity
[32,130]. Immature virions are 14 times stiffer than ma-
ture particles [32]. The structural rearrangements associ-
ated with p55Gag maturation by the viral protease
transform the stiff immature viral particle into a mature
particle with a thin protein shell and conical core; its
ability to enter cells depends on its softness [32,130].
p55Gag maturation by the viral protease into its distinct
components is a regulated and sequential process with
particular kinetics [131]: the first cleavage is that of the
SP1-NC, and it induces the structural switch of Gag that
controls maturation and activates Env [54,99]. STED mi-
croscopy has recently provided visual evidence of such
regulation: Env spikes at the surface of mature virions
coalesce into foci, whereas in the less infectious imma-
ture virion, Env spikes remain scattered across the vir-
ion surface [33]. Proteolytic maturation of p55Gag
allows Env lateral motility and clustering into foci
[33,132]. However, although truncation of the gp41-CT
also favors Env motility on immature particles, it does
not result in Env clustering: this provides evidence that
gp41-CT-mediated Env clustering optimizes viral in-
fectivity [33,132], confirming prior reports showing that
LLP-1 and LLP-2 mediate Env clustering [55], partly via
Arg residues [56]. Pang et al. [32] recently used atomic
force microscopy to demonstrate a correlation between
viral infectivity and virion stiffness. Using different con-
structs that separate the Env ‘fusion-activity’ (EnvΔCT
construct) from the ‘stiffness/softness properties’ (GFP-
gp41-CT construct), they found that the gp41-CT stiffens
immature virions in a concentration-dependent fashion,
thereby impairing infectivity of immature (but not mature)
particles [32]. Because VSV-G pseudovirions were simi-
larly affected, the authors conclude that particle stiff-
ness directly regulates immature viral entry [32].
Intriguingly, there was no direct interaction between
the EnvΔCT and the GFP-gp41-CT constructs, imply-
ing that the gp41-CT directly stiffens immature viral
particles, and that virion stiffness controls virion fu-
sion capacity [32]. These studies indicate biophysical
mechanisms underlying the control of viral infectivity
by protease-mediated p55Gag cleavage [32,33,132]. Al-
though both groups related viral infectivity to viralstiffness, they draw opposite conclusions about the
roles of viral stiffness and of the gp41-CT: Chojnacki
et al. [33] propose that the stiffness of the immature
particle interferes with Env motility and clustering
through the gp41-CT, whereas Pang et al. [32]
propose that it is viral stiffness itself that is controlled by
the gp41-CT through an as yet undefined mechanism pos-
sibly involving the arrangement or stability of the immature
Gag shell. In other words, stiffness impairs Env motility and
gp41-CT-mediated Env clustering and infectivity [33,132],
or, alternatively, stiffness is a consequence of the presence
of the gp41-CT [32]. Either way, Env ensures minimal fu-
sion until the virus is mature, suggesting a mechanism
whereby unprocessed p55Gag “withholds” Env until full
maturation by the viral protease is complete through an
inside-out regulation mechanism [54,58,129].Control of viral infectivity
The p55Gag precursor is trafficked to and accumulates
at the plasma membrane where it recruits viral compo-
nents (including Env, viral genomic RNA, viral accessory
proteins). However, interactions of the gp41-CT with
cellular trafficking regulators (discussed below, ‘Interac-
tions of the gp41-CT with cellular factors and intracellu-
lar regulators’) down-modulates Env as soon as it
reaches the plasma membrane such that it remains
scarce until p55Gag oligomerization is complete or, at
least, sufficiently dense in the assembly platforms to en-
sure efficient viral assembly and release [133] (Figure 3).
This mechanism for the regulation of the surface abun-
dance of Env protein may protect infected cells from Env-
dependent cytopathic effects, from Env-induced Fas-
mediated apoptosis and/or from Env-specific immune
responses [133-137]. During, or shortly after virus release,
the viral protease cleaves the p55Gag and p160GagPol
precursors, resulting in structural and morphological
rearrangements of the virion that enable Env fusion
capacity [47,54,129]. gp41-CT interacts with p55Gag with
higher affinity than with mature MA [129], and this loos-
ened interaction probably favors changes in Env conform-
ation after viral maturation [47,54] and Env lateral
motility [33]. With the completion of maturation, the
virion becomes maximally infectious and can start a new
round of infection. The scarcity of Env spikes at the
surface of virions appears to be a compromise between ef-
ficient fusion capacity, through virion softness, clustering
of Env into foci, and immune escape.
This mechanism for controlling infectivity differs from
that of other retroviruses, such as Murine Leukemia
Virus and Mason-Pfizer monkey virus, where the viral
gp41-CT is cleaved by the viral protease in the released
virion, resulting in Env becoming fusion competent
[138,139].
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Clearly, p55Gag is the main pillar of HIV assembly, and
recruits the constituents of HIV virions, orchestrates
their assembly and controls infectivity of viral particles.
Nevertheless, many questions concerning Env recruit-
ment and incorporation into virions remain unresolved.
Do p55Gag and Env interact directly or is this interaction
indirect? Or, alternatively, are there many contact points,
both direct and indirect? In this case, are these multiple
interactions permanent and simultaneous, or is there a
sequential order important for the control of viral as-
sembly and/or infectivity? Which Env determinants are
involved? Many cellular proteins have been described to
interact with the gp41-CT (detailed below, section ‘In-
teractions of the gp41-CT with cellular factors and intra-
cellular regulators’), but it is not known which bridge
the p55Gag/Env interaction and which serve other pur-
poses. It is unclear which are, as a consequence, incor-
porated in newly synthesized viral particle, and if they
are, whether they are included passively or contribute to
the initial steps of the following infection round.
Phenotypes of gp41-CT truncations
Despite numerous studies addressing the role of the gp41-
CT domain, the roles of particular determinants remain
poorly documented. One reason why the gp41-CT
remains poorly understood is that the effects of gp41-CT
truncations and/or mutations are cell-type dependent. For
example, many transformed T-cell lines (e.g. the cell lines
H9, MT-2, Jurkat, and CEMx174) and primary target cells
of HIV (primary CD4+ T cells and macrophages) do not
sustain replicative spread of viruses with a truncated
gp41-CT; these cells are referred to as ‘non-permissive’ for
gp41-CT truncation. Other cells, in contrast, such as the
T cell lines MT-4 and C8166 and several laboratory cell
lines (HEK293T, HeLa, and COS) are less affected by full
or partial truncations of the gp41-CT and sustain replica-
tion of the corresponding viruses (termed ‘permissive’
cells) [43-45,119,120,140-142]. Truncation of gp41-CT de-
creases Env incorporation into virions by about 10-fold in
‘non-permissive’ cell lines and in primary HIV target cells
(i.e. primary PBMCs and monocyte-derived-macrophages),
but has a much smaller effect in ‘permissive cells’
[119,120]. An illustrative example, albeit extreme, is that
truncation mutants have different effects in macrophages
[119], perhaps owing to differentiation and culture condi-
tions. Compromised infectivity and replication capacity
in ‘non-permissive’ cells has been linked to altered
localization of the viral capsid that failed to accumulate
and polarize at the viral synapse [119,120], but not to in-
creased gp120 shedding from virions nor to reduced Env
cell-surface expression [110,119,120,140]. HIV and SIV
viral particles contain relatively small amounts of Env (~7-
14 Env trimers/virion) [143-145], due to both the massiverecycling of neo-synthesized Env and to Env shedding.
These findings and comparisons are thus difficult to inter-
pret and their biological relevance is unclear.
It is not clear how gp41-CT truncations may impact
Env incorporation into virions without affecting Env
expression at the PM or Env trafficking through the ER
and Golgi networks, as one could expect Env incorpor-
ation into virions to be related to the amount of Env at
the PM. One possible explanation is that inherent differ-
ences between cell types in the expression or localization
of host factors play a role in viral assembly; this would
account for the cell-type dependent phenotypes of gp41-
CT truncations and mutations. A second possible ex-
planation is that because the gp41-CT activates the NF-κB
canonical pathway [79], gp41-CT truncations interfere
with the cell activation status (see section ‘Activation of
transcription’). Cell types and cell lines differ in their
basal activation levels and in their dependence on
NF-κB, and it is therefore conceivable that truncations
of the gp41-CT could translate into cell-type-dependent
phenotypes [31].
One recent study [141] compared the infectivity of
sub-saturating titers of wild-type and of a HIV-1 gp41-
CT-truncated mutant in various gp41-CT truncation
‘permissive’ (MT-4, C8166) and ‘non-permissive’ (H9,
MT-2, Jurkat, CEM-SS) cell lines: the ‘permissive’ and
‘non-permissive’ phenotypes of target cells correlated with
the level of gene expression, and particularly of p55Gag pro-
duction and processing to mature capsid (CA), rather than
with Env incorporation into the virion [141]. In ‘non-per-
missive’ cells, viral assembly was compromised as a conse-
quence of p55Gag failing to accumulate and polarize at the
viral synapse (VS), whereas in ‘permissive’ cell lines, high
levels of p55Gag overrode and compensated for the absence
of the gp41-CT [141]. This study could reconcile the cell-
type dependence of Env incorporation with a dual role for
the gp41-CT, being involved in Env incorporation into
virions and polarized budding on one hand and in cell acti-
vation and regulating viral gene transcription on the other.
The situation is more clear-cut for the SIV gp41-CT.
SIV Env truncations have been reported to arise spon-
taneously when culturing SIV in human cell lines, and
then to revert back following culture in simian cells
[146-149]. These truncations increased Env surface ex-
pression, fusogenicity [61,150] and infectivity in vitro
[147,151]. These SIV gp41-CT truncation mutants are
replication competent both in vitro and in vivo, but lack
full pathogenicity in vivo: macaques infected with a
LLP-1- and LLP-2-defective SIVmac239 initially had
viremia, but the viral load declined with time to below
the detection threshold; the infected macaques never
progressed to AIDS [152]. A similar phenotype has
been reported for HIV-2 [147,153]. Spontaneous trun-
cations of the gp41-CT of SIV cultured in human cell
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presence of a restriction factor whose action is
inhibited by the gp41-CT in rhesus cells, but which is
absent from human PBMCs or ineffective against SIV
[79]. Alternatively, spontaneous truncations of the
gp41-CT in human PBMCs or T cell lines may improve
viral infectivity by enhancing Env expression and
thereby incorporation into virions. The truncation of
the SIV gp41-CT observed in human cell lines may re-
move signals mediating Env trafficking such that the
higher Env density at the surface of SIV virions is pre-
served. Further studies to elucidate how these phenom-
ena are related and the real consequences of Env levels
in the virion may reveal new leads for the development
of strategies to control viral assembly.
Interactions of the gp41-CT with cellular factors and
intracellular regulators
A number of cell factors have been described to interact
with the gp41-CT: in some cases, the interactions have
simply been described without any evidence of signifi-
cance, and in others, the significance is controversial.
Nonetheless, most of these interactions between the gp41-
CT and cellular factors contribute to improving viral repli-
cation, by promoting viral gene expression, enhancing viral
infectivity, or interfering with intrinsic cellular restriction
factors or immunity. Innate immunity has developed many
(often interferon-induced) pathways to counter gene ex-
pression and the late stages of the viral replication cycle,
namely assembly and budding, as these are essential steps
for viral propagation. It seems likely that such factors are,
at least in part, responsible for the cell-type-dependent
phenotypes observed.
Figures 3 and 4 summarize cellular and viral proteins
interacting with the gp41-CT and their intracellular
localization.
Env trafficking and sorting through the trans Golgi network
(TGN)
Golgi retrieval signals function to return proteins which
have left the Golgi to that compartment; Golgi retention
signals, by contrast, are generally found in the transmem-
brane domain of Golgi and ER resident proteins. The main
Golgi retrieval signals are cytoplasmic domain tyrosine-
based or dileucine motifs [154,155]. The gp41-CT contains
both Golgi retrieval (tyrosine-based and dileucine-based)
and Golgi retention motifs [156]. They regulate Env
trafficking through the endocytic pathway [157-159].
AP-mediated Env endocytosis
As soon as Env comes into contact with the plasma mem-
brane, it is endocytosed. Time course analyses show that
50% of Env, but only 15% of a gp41-CT-truncated Env, is
internalized after 60 minutes [157]; and similar timecourses have been reported using a chimeric CD4 mol-
ecule fused to the gp41-CT [156]. These observations in-
dicate that the gp41-CT mediates endocytosis. Env is
endocytosed via interactions with the clathrin adaptor
complex (AP proteins) [157-159]. Clathrin adaptors sort
and direct proteins through the endocytic pathway. The
highly conserved Y712SPL motif of HIV (and Y721XXΦ of
SIV) immediately downstream from the transmembrane
region has been implicated in regulating Env intracellular
trafficking by binding clathrin adaptor AP-2 μ (medium)
chains [157-159] (Figures 3 and 4). The Y712SPL motif can
also interact with the AP-1 and AP-3 adaptor complexes
through μ1 and μ3A, respectively [159]. Whereas the
interaction of the gp41-CT Y712SPL motif with AP-2 leads
to Env internalization, interaction with AP-1 regulates Env
trafficking through the TGN and addresses Env to the
basolateral PM in polarized cells [159] (Figures 3 and 4).
The AP-2 adaptor complex also mediates p55Gag internal-
ization through Y132 and V135 at the MA-CA junction
[160], and the AP-1 μ [161] and AP-3 β and δ subunits
contribute to p55Gag release. They do so by transporting it
to intracellular sites of active budding, such as MVBs and
the PM [162,163] and/or by facilitating its interaction with
other cellular partners such as Tsg101 [161]. The inter-
action between Env and various proteins of the AP
clathrin adaptor complex may therefore be involved in the
p55Gag/gp41-CT interaction and determine the fate of Env
(targeting to the lysosomal compartment for degradation,
or to the basolateral plasma membrane for incorporation
into virions).
Y712SPL-mediated endocytosis is suppressed in the pres-
ence of the HIV-1 p55Gag precursor polyprotein [133,164].
This suggests that p55Gag interferes with the Env/AP-2
interaction and that the amount of Env at the cell surface
is regulated by the AP-2 versus p55Gag balance. AP-2 may
thus eliminate any Env protein that is not associated with
p55Gag and that is therefore not destined for incorporation
into virions [133,164]. Env internalization may proceed
until sufficient p55Gag has been synthesized and has accu-
mulated at the site of viral assembly, at which point, p55Gag
would interact with Env directly or indirectly, thereby trap-
ping Env into the nascent virion [133,165]. In the case of
SIV, mutating the Y721 in agp41-CT truncated Env resulted
in increased Env expression at the plasma membrane,
whereas mutations of Y721 in a full-length gp41-CT context
had little impact on Env expression at the plasma mem-
brane [123,166]. Presumably, other motifs involved in
endocytic regulation overcome the single mutation.
Additional distal determinants also regulate Env internal-
ization [164]. These have now been identified as being the
most distal C-terminal dileucine motif [167,168] and/or
IS1 and IS2 Golgi retention sequences [156]. Recruitment
of AP-1 [167] and AP-2 [168] by the most C-terminal
dileucine motif ensures correct post-Golgi routing of Env,
Figure 4 gp41-CT domains or AA with reported function(s), conservation across subtypes, interacting partners and role of these
interactions. Abbreviations: RER: rough endoplasmic reticulum; TGN: trans Golgi network; CaM: calmodulin; LLP: lentiviral lytic peptide; TAK:
TFG-β-activating factor; AP: adaptor protein: TIP-47: Tail-interacting protein 47 kDa; Ub: ubiquitin.
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with the membrane-proximal Y712SPL motif [167,168]
(Figures 3 and 4).
Both the Y712SPL motif and the most C-terminal
dileucine motif are extremely well conserved across HIV-1
subtypes (except subtype C), and also in HIV-2 and SIV
strains, evidence of their importance (Figure 1B). Similar
signals in cellular proteins or in the glycoproteins of other
viruses (e.g. alpha herpesviruses) affect endocytosis as well
as intracellular trafficking in endosomes and the TGN,
and can determine basolateral versus apical sorting
(reviewed in [169,170]). It is nevertheless intriguing that
subtype C viruses harbor a LQ rather than LL (dileucine)
at this position in over 60% of cases. As the requirement
for an intact C-terminal dileucine motif for correct inter-
action with AP-1 and with Nef (see below, section ‘As-
sembly’) seems to be quite stringent [167], these
observations raise three possibilities: (i) other motifs
are involved, or (ii) Env trafficking differs between sub-
types, and differences in sub-cellular localization are
less detrimental to viral assembly and infectivity than
previously believed, or (iii) subtype C Env internaliza-
tion is less efficient and more Env is expressed at the
surface of infected cells and possibly on virions ofsubtype C than of other subtypes; this could be a cause
or consequence of the weaker antibody response or of
the lower replicative capacity.
Another tyrosine-based motif, Y768HRL, is present in
the gp41-CT. Although this motif also interacts with
AP-1, AP-2 and AP-3, it is not involved in endocytosis
of Env, perhaps because of its localization in the gp41-
CT, but may mediate NF-κB gene expression [79] (see
below, section ‘Activation of Transcription’). Likewise, one
or two other YxxΦ motifs are present in various SIV
strains and in HIV-2, but none has been shown to mediate
endocytosis [166].
Golgi retention
Most Env is retained in the ER, and from there
ubiquitinated and degraded by the proteasome. Only a
small proportion actually reaches the Golgi and proceeds
to the cell surface. Nevertheless, Env is also retained in the
Golgi [156]. The IS1 (AA 750–763) and IS2 (AA 764–785)
regions in the gp41-CT reduce Env surface expression by
retaining Env in the Golgi, independently of AP-1 and AP-
2 [156] (Figure 4). These sequences include LL (or IL mo-
tifs, which behave similarly to LL in Golgi retrieval [171]),
and result in retention in the Golgi of gp160 and of
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CD4 receptor or to immunoglobulin extracellular/trans-
membrane domains. These sequences are also highly con-
served across subtypes [156] (Figure 1B).
TIP47
The leucine-zipper domain, LLP-3, also contains a highly
conserved Y802W803 diaromatic motif. This motif has
been found to be involved in the retrograde transport of
Mannose-6-Phosphate Receptors and in lipid droplet
biogenesis. The Y802W803 motif in Env ensures the retro-
grade transport of Env from late endosomes to the TGN
(Figure 3) and thereby contributes to the regulation of
the intracellular distribution of Env, and to Env incorp-
oration into the virion, particularly in macrophages
[165,172-175]. Lopez-Vergèz et al. reported that TIP47
is required for the p55Gag/gp41-CT interaction [165].
Disruption of the p55Gag/TIP47 interaction through mu-
tations in MA or by TIP47 knock-down causes p55Gag
to localize in scattered dots in the vicinity of the PM.
These observations led to the suggestion that TIP47 acts
as a linker between Env and p55Gag, and serves as a
bridge for efficient Env incorporation [175]. However,
other authors report not being able to reproduce these
findings [25].
Rab7A and other RabGTPases
Rab proteins are early and late-endosome associated
GTPases that regulate specific steps in intracellular mem-
brane trafficking. They recruit tethering, docking and fu-
sion factors, as well as the actin- and microtubule-based
motor proteins that facilitate vesicle traffic [176-180]. In a
study aiming to identify cellular trafficking factors in-
volved in HIV assembly and budding, Caillet et al. report
that Rab4A, Rab6A, Rab8A, Rab9A, and Rab11A moder-
ately decreased viral infection (by 30-60%) in HeLa cells,
probably in relation to their roles as regulators of the
exocytic pathway [173,181,182]. Rab7A knock-down
resulted in a > 30-fold decrease in viral propagation [182].
Rab7A is involved in regulating exit from the late endo-
some/MVB by controlling the maturation and fusion of
late endosomes and phagosomes with lysosomes, their
intracellular motility when loaded with lipids, and their
interaction with the cytoskeleton for migration along mi-
crotubules [176,178-180,183-185]. Of particular interest is
the finding that Rab7A has a dual activity. Rab7A knock-
down experiments using siRNA also showed that Rab7A
regulated and allowed gp160 processing to gp120 + gp41
and incorporation of mature Env into particles (Figure 3).
The authors propose that Rab7A may either ensure cor-
rect Env trafficking through furin-containing compart-
ments, or ensure appropriate co-localization of Env
and/or of furin; alternatively, Rab7A may modulate Env
expression, and in the absence of Rab7A, Env isexpressed to levels that exceed the processing capacity
of furin [182].
Rab7A knock-down also interfered with viral release,
resulting in the accumulation of gp160 and viral compo-
nents at the PM, reminiscent of a BST-2/Tetherin pheno-
type [182]. The authors report that Rab7A is required for
sorting BST-2/Tetherin to lysosomes for degradation
through molecular mechanisms that remain to be eluci-
dated [182] (Figure 3). Rab7A is also involved in the late
maturation of the final autophagic vacuoles [186,187].
Strikingly, the role of Rab7A shares similarities with
that of Nef (see section ‘Nef ’ below) in mediating in-
creased Env at the PM [188] and in intercepting the au-
tophagic processing of Gag to increase virion assembly
and egress [189,190]; both also affect traffic through the
endocytic pathway [106]. It would be interesting to find
out whether Nef intersects the Rab7A or Rab5 signaling
cascades.
Rab9A is a mediator of late endosome-to-TGN traffick-
ing involved in the replication of many viruses, including
Marburg Virus, Filoviruses and Measles. It interacts with
TIP47 and PRA1 (prenylated Rab acceptor 1), both cellu-
lar interacting partners of gp41-CT [173]. PRA1 has been
reported to interact with lentiviral gp41-CT (SIV, HIV-1
and 2, EIAV and FIV) in a 2-hybrid system [191] without
modulating viral release, infectivity or Env incorporation
[192]. The significance of these interactions remains
unclear, but as both Rab9A and PRA-1 are involved in
vesicular trafficking, it is possible that they participate in
regulating Env trafficking through the Golgi.
Assembly
Detergent-resistant lipid rafts
Detergent-resistant lipid rafts are cellular microdomains
enriched in cholesterol and sphingolipids and which
contain proteins. Lipid rafts are thought to play an import-
ant role in many cellular processes including signal trans-
duction, membrane trafficking, protein oligomerization,
cytoskeletal organization, and pathogen entry (reviewed in
[193-195]). Lipid rafts are thought to be central to the
assembly and infectivity of numerous enveloped viruses,
including lentiviruses. The lipid bilayer of HIV virions is
highly enriched in cholesterol and sphingomyelin, both of
which are major components of lipid rafts [196,197]. Also,
p55Gag and Env and have been co-localized with lipid raft-
associated proteins [73,85-87]. Env incorporation into lipid
rafts optimizes its incorporation into virions and confers
viral infectivity [198]. Conversely, excluding HIV from lipid
rafts impairs viral infectivity [85,199-203]. The 12 C-terminal
amino acids of LLP-1 and portions of LLP-3 [43,44,49,204],
and also palmitoylated cysteines C764 and C837, and bulky
hydrophobic side chains, have been implicated in targeting
Env to lipid rafts [198,205] (Figure 4). In contrast to the
reports by Bhattacharya [198,206], Chan et al. [207] found
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cant effect on Env expression, trafficking, interaction with
lipid rafts and incorporation into virions, or on the fusion
efficiency or infectivity in single-cycle infections, despite
decreased palmytoylation of Env [207].
Other studies argue against any substantial direct
targeting of Env to lipid rafts, and suggest, rather, that it is
p55Gag that recruits and anchors Env to lipid rafts [85].
Various observations imply that p55Gag drives Env to lipid
rafts. First, mutation of residue S4 in MA abolishes the
interaction of p55Gag with lipid rafts resulting in reduced
Env incorporation into virions, presumably by inhibiting
the ability of p55Gag to target or hold Env within raft
microdomains [208]. Second, independent studies have
reported that in the absence of p55Gag, or in the presence
of MA or gp41-CT mutations that abolish Env incorpor-
ation into virions, Env was not found associated with
detergent-resistant membranes [198,206]. The obser-
vation that neither the cysteine residue in LLP-1 nor
the presence of bulky AA is conserved between sub-
types raises further doubts about a direct interaction
between Env and lipid rafts. This polymorphic flexibil-
ity is more consistent with the view that Env is
recruited to lipid rafts through p55Gag, and/or that
other determinants are also involved. Nonetheless, it
cannot be excluded that under certain circumstances,
particularly in transfection experiments involving
strong viral gene overexpression, Env may be passively
incorporated into virions; a phenomenon of this type
would explain the contrasting results reported.
In the cases of other enveloped viruses, such as Influ-
enza Virus [209] and Respiratory Syncytial Virus [210],
the matrix/lipid raft interaction is favored by, or even
dependent on, the presence of the respective envelope
cytoplasmic tails. Whether lentiviral gp41-CTs also
somehow influence the MA/lipid raft interaction has
not been described.
Nef
Interplay between the Env gp41-CT and the viral
accessory protein Nef has been reported to increase viral
infectivity [211,212]. The viral accessory protein Nef is a
pleiotropic non-enzymatic, myristoylated, HIV and SIV
lentivirus pathogenesis factor. Nef increases viral
infectivity through various, not fully elucidated, mecha-
nisms involving immune escape [213-216] (reviewed in
[217]), increased viral infectivity and propagation
[106,212,218-222], and perturbed immune activation,
thereby promoting a favorable environment for viral
replication [90,216,219,223-227]). Most of Nef ’s func-
tions are due to its ability to influence the cellular en-
vironment, mainly through protein-protein interactions
which interfere with cell-receptor trafficking or are in-
volved in T cell receptor (TCR)-induced signaling [228].It has been proposed that Nef promotes Env gp160 pre-
cursor processing and PM expression of the mature gp120
and gp41 products by abrogating their retention in the cis-
Golgi [106,212], and by specifically augmenting Env accu-
mulation at the PM [212]. Enhanced Env at the PM was
found to be dependent on the C-terminal dileucine motif
of the gp41-CT and on the C-terminal residues of Nef
(positions 181–210), and it was suggested that Nef in-
creases Env incorporation into virions [212]. Whether the
gp41-CT Golgi retention sequences IS1 and IS2 are also
involved has not been investigated.
Others have proposed that Nef may modulate cell sig-
naling thereby altering intracellular trafficking and
augmenting Env accumulation in late endosomes/MVBs
[106]. Nef-insensitive Env glycoproteins from various
enveloped viruses share pH-dependence (Influenza-HA,
VSV-G and HCV), and most importantly, lack endocytic
traffic motifs, budding in compartments other than
MVBs (HCV) or at the cell PM (Influenza-HA, VSV-G).
Glycoproteins needing Nef for optimal assembly harbor
determinants of intracellular trafficking through the
endocytic pathway and assemble in MVBs [106,229].
Furthermore, the role of Nef in Env and p55Gag precur-
sor co-localization could be linked, at least to some ex-
tent, to Gag expression levels, and this may explain the
cell-dependence and the gp41-CT ‘permissive’ versus
‘non-permissive’ phenotypes. The incorporation into
pseudovirions of some retroviral and lentiviral Envs is
increased in the presence of Nef, but not for those for
which Env incorporation was already optimal [106].
Sandrin et al. conclude from these observations that Nef
expression optimizes co-localization of retroviral Envs
with p55Gag in late endosomes/MVBs specifically for
those Envs that inherently do not accumulate in the
endosomal pathway [106]. This is consistent with the
observation that Nef [231-233], the gp41-CT [167,168]
and p55Gag [160-163] all interact with adaptins AP-1
through 3, suggesting these intermediates may be
involved. It would be interesting to assess whether this
observation is relevant to the findings of another study:
the absence of the scaffold protein Dlg1 was described
to restrict late steps of the HIV cycle due to Gag and
Env rerouting and sequestration in a tetraspannin-rich
(CD63+ and CD82+) late-endosome and plasma-
membrane-related compartment [230].
Nef also interacts directly with the p55Gag and
p160GagPol precursors via p6* in the overlap region
between p6 and pol [234,235], and increases p55Gag and
p160GagPol processing and egress via AIP-1/ALIX, a critical
intermediate in the formation and proliferation of
multivesicular bodies (MVBs) [221,233,234]. It has been
suggested that the Nef-induced p55Gag accumulation in
late endosomes/MVBs is linked to autophagy. Autophagy
is a cell survival and host defense mechanism by which
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starvation and microbial invasion; it involves clearing
damaged organelles, macromolecular aggregates and
intracellular microbes through double-membrane vacu-
oles, termed autophagosomes, which typically mature into
amphisomes or autolysosomes after fusing with MVBs or
lysosomes [236-238]. Nef has been suggested to increase
virion assembly and egress by intercepting the autophagy
process [189,190]; however, the mechanisms of HIV
p55Gag incorporation into the autophagosome leading to
the release of HIV Gag particles into the extracellular en-
vironment remain largely unknown.
It is important to keep in mind, however, that recent
work to identify the localization of HIV assembly in dif-
ferent cell types, and particularly in 293T cells and in
macrophages, were performed using viral-like particles
(VLPs) and VSV-G pseudotypes which target the
p55Gag precursor to the PM. From there, it either
buds releasing new infectious viral particles or is en-
docytosed and accumulates in late endosomes and
MVBs [80,81,239]. Most of these studies are based on
the use of VLP and of pseudovirions comprising a
heterologous Env, and on large p55Gag or VLP/
pseudovirion input, i.e. high Gag overexpression. The
precise fate of p55Gag precursor protein that has not
budded from the PM and that has been endocytosed
into late endosomes and MVBs is not known; more im-
portantly, it remains to be established how and where
Env and Nef interplay with the p55Gag precursor to
allow the release of fully infectious virions.
The Nef/gp41 interplay also involves other mecha-
nisms independent of the gp41-CT and of its trafficking
domains. Another function of Nef is to promote the bio-
genesis of viral assembly platforms including rafts and
MVBs [221,222]. Nef can accumulate in lipid rafts and
thereby contribute to infectivity of progeny virions by in-
creasing the incorporation of lipids into viral membranes
[222]. Whether Nef further favors or stabilizes the insuf-
ficient interaction of Env with lipid rafts, in conjunction
or not with Gag, is still not known. In another study, the
N-terminal region of Nef and its myristoylated moiety was
shown to decrease the sensitivity of the gp41 ectodomain
to neutralization by antibodies targeting the MPER epitopes
that are embedded in the virion lipid bilayer (2F5 and
4E10) [240-242] and thereby contribute to viral escape from
the humoral immune response [243]. This activity did not
affect Env incorporation into virions, and the authors sug-
gest that the susceptibility of neutralization to these epi-
topes may be modulated by Nef-mediated alteration of the
lipid bilayer composition [243].
The consequences of Nef deletions, like those
of gp41-CT truncations, are cell-type dependent
[244,245]. In ‘Nef non-permissive’ cells, Nef deletion af-
fects the early stages of viral infection and only slightlymodulates the late stages of the viral replication cycle
(assembly, release and maturation) [244,245]. Although
there has been no direct pair-wise comparative study of
gp41-CT truncations and Nef deletion mutants to our
knowledge, it is interesting that there is some overlap be-
tween the gp41-CT and Nef ‘permissive’/’non-permissive’
phenotypes (e.g. MT-4 cells are ‘permissive’ to both,
whereas primary CD4 cells and macrophages, and H9,
Jurkat and CEMx174 cells are ‘non-permissive’ to both
[119,120,244,245]). The reported effects of gp41-CT trun-
cations and of Nef deletions on viral replication can differ
in a given ‘non-permissive’ cell type (e.g. C1866 cells are
‘permissive’ to gp41-CT truncations [119,120] but are par-
tially ‘non-permissive’ to Nef truncations) [244,245],
although such comparisons should be interpreted with
caution as the results come from different groups with dif-
ferent experimental set-ups. Day et al. reported that the in-
corporation of an Env Y712A mutant into virions was
impaired in the absence of Nef in MT-4 cells but not in
HEK293 cells [211]. This is intriguing because MT-4 cells
are ‘permissive’ to both gp41-CT truncation and Nef dele-
tion. One would have expected the Env Y712A ΔNef
double mutant not to display impaired Env incorporation
when produced in this cell type. One possible explanation
is that in gp41-CT ‘permissive’ cells, Nef plays a “compen-
satory” role: in the absence of Nef, the gp41-CT ‘permissive’
cell-line becomes ‘non-permissive’ to gp41-CT mutations.
Alternatively, the correct routing of Env and/or Nef to
intracellular trafficking compartments may play a crucial
role in viral assembly and Env incorporation. Mutations
disrupting the Y712SPL endocytic motif and truncation mu-
tants may behave differently.
Calmodulin
Calmodulin is a calcium-induced mediator of FAS-
mediated apoptosis. The gp41-CT binds calmodulin
[246,247] and induces apoptosis of T cells, thereby ac-
counting for most of the CD4+ T cell decline that
characterizes HIV infection [134,248]. Amino acids
Ala835, Ala838 and Ile842 of LLP-1 have been identified as
being involved in calmodulin binding and inducing Ca2+
flux and DNA fragmentation in transfected cells
[134,136,137,246,247] (Figure 4). Point mutations of the
gp41-CT (A835W, A838W, A838I, and I842R) eliminate
co-immunoprecipitation of Env with calmodulin but have
no significant effect on viral production or Env expression
[135,137]. Therefore, active Env cycling through the
endocytic pathway may prevent Env-mediated apoptosis
and thereby avoid premature cell-death and ensure viral as-
sembly [133,164]. Because the gp41-CT/calmodulin inter-
action is deleterious to the virus by itself, it is likely that this
interaction is “collateral damage” from other actions of cal-
modulin in viral assembly. These other actions include en-
suring the conformational changes of MA so as to expose
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platforms at the PM [73,86,87,93,94,98].
Although independent reports have described Ala835
as being the calmodulin-binding site [136,137], Ala835 is
not conserved across clades, and there is a Leu, Ile, Thr
or Phe at the corresponding position in some strains.
Possibly, polymorphism at this position explains the di-
verse calmodulin-binding activity of Envs and correlates
with their apoptotic potential; indeed, the A835W muta-
tion used in many studies fully abolishes the ability of
the gp41-CT to bind calmodulin. If this were the case,
late, more cytopathic or apoptosis-inducing Envs would
be expected to all have an Ala835 and to bind more cal-
modulin, whereas the less pathogenic, early and chronic-
infection viral isolates would be expected to bind less
calmodulin and be more polymorphic at this position.
Prohibitin1/2
The dileucine motifs of LLP-2/LLP-3 (AA 790–800), and
more specifically the dileucine motif L799L800 immedi-
ately upstream from the Y802W803 diaromatic motif, has
been found to interact with prohibitin 1/2 (Phb) [249].
These proteins are produced almost ubiquitously; they
are localized in numerous cellular compartments includ-
ing mitochondria, the plasma membrane PM and
the nucleus, and are also associated with lipid rafts. Dis-
ruption of the gp41-CT/Phb association, like gp41-CT
truncation mutants, impairs cell-to-cell transmission in
‘non-permissive’ cells [249] (Figures 3 and 4). It is however
not known whether this association genuinely contributes
to the cell-to-cell transmission capacity of diverse HIV
Envs or whether they are passively bound to gp41 at the
time of assembly into lipid rafts. The L799L800 motif is not
conserved between subtypes and is in many cases replaced
by Val, particularly in subtype C. Nonetheless, in this
work, the gp41-CT/Phb association was disrupted only
when both Leu residues were mutated: single mutants
were unaffected [249]. These findings suggest that this
interaction, or interactions of this L799L800 motif with other
cellular factors, is important enough to be preserved des-
pite sequence variation. Moreover, this motif is also in-
volved in interacting with p155-RhoGEF to block RhoA
activation [250,251] (see section ‘Activation of transcrip-




It was recently shown that the gp41-CT of HIV-1 activates
NF-κB via the canonical pathway by interacting directly
with TFG-β-activated kinase 1 (TAK1) [79]. TAK1 acti-
vates the transcription factors NF-κB and AP-1. TAK1 is
itself activated by cytokines and microbial pathogens,
and phosphorylates IκB, routing it for proteasomaldegradation, thereby allowing NF-κB to translocate into
the nucleus [252]. The gp41-CT/TAK1 interaction maps
to the N-terminus of LLP-2 (C764-L775) and involves Y768
in the second YxxL motif [79] (Figures 3 and 4). The HIV-
1 LTR contains 2 (or 3, depending on subtype) NF-κB
-binding sites [253]. The authors show that HIV mutants
lacking the NF-κB-activating domains were more heavily
dependent on cellular activation for replication, and
thereby elegantly demonstrated that the gp41-CT contrib-
utes to viral replication in sub-optimally activated T lym-
phocytes by inducing the canonical NF-κB pathway [79].
In the case of SIV, the gp41-CT also activates the NF-κB
pathway, but by acting upstream from TAK1, on a factor
that has not yet been identified [31]. One of the functions
of SIV and HIV Nef is to increase cellular activation
in a manner similar to that induced by TCR engage-
ment [90,228,254-257] in a NF-κB-independent manner
[224,226,258,259]. Consequently, it has been suggested
that Nef and Env may act in concert to progressively and
steadily activate gene expression resulting in a positive
feedback loop [79]. Alternatively, the early viral gene prod-
uct Nef and the late gene product Env gp41-CT may act
at different times or stages in the viral replication cycle,
and induce different activation pathways [79], thereby ful-
filling the requirement for two independent stimuli to fully
activate T cells [260,261].
Luman
Luman (LZIP or CREB3) is a transcription factor belong-
ing to the CREB/ATF family; it has been linked to the
endoplasmic reticulum (ER) stress response. Luman acti-
vates the transcription of genes involved in ER-associated
degradation of unfolded proteins [262-264]. The ER-
membrane-bound form of luman is inactive; proteolytic
cleavage releases an active form which enters the nucleus
[263]. This activated form of luman interferes with Tat-
mediated HIV transcription [265]. gp41-CT interacts with
the ER-bound inactive precursor of luman, decreases its
stability and targets it for degradation, thereby indirectly
promoting LTR-mediated transcription (Figure 3). This
interaction maps to residues 751–768, the region lying
between the KE and LLP-2 [265] (Figure 4), and partly
overlaps the gp41-CT region that interacts with TAK1
(C764-L775) [79]. Whether these two mechanisms some-
how overlap or converge has not been explored.
P115-RhoGEF
Activation of RhoA through p155-RhoGEF inhibits HIV
replication by affecting gene expression [251]. The gp41-
CT of HIV interacts with p155-RhoGEF and thereby
relieves the RhoA-induced inhibition [250,251]. This inter-
action involves L799 in LLP-3. L799 is highly conserved,
and is part of the dileucine motif interacting with Phb1/2
[249] which tolerates polymorphic changes (Figure 4).
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p115-RhoGEF impair HIV-1 replication in the human
Jurkat T cell line (‘non-permissive’ to gp41-CT trunca-
tions) [250,251]. p155-RhoGEF is a specific guanine
nucleotide exchange factor (GEF) involved in actin cyto-
skeletal organization rearrangements [250] through activa-
tion of RhoA GTPase, which is in turn involved in actin
stress fiber organization, cell cycle progress through G1
and cell proliferation. Nonetheless, the gp41-CT-mediated
relief of RhoA-mediated viral inhibition seems to be inde-
pendent of the stress fiber formation function of RhoA
and to involve other, as yet unknown, RhoA-mediated
mechanisms [251]. Furthermore, whether this viral inhib-
ition also applies in ‘permissive’ T cells or whether it is
restricted to ‘non-permissive’ is not known: both relevant
studies used ‘non-permissive’ cells. Comparisons between
‘permissive’ and ‘non-permissive’ cells may provide some
clues as to the mechanism of action of this cellular factor
in the HIV replication cycle.
Immune evasion: countering intrinsic restriction/
countering antiviral restriction factors
Tetherin
Tetherin (BST-2 or CD317) is an interferon-inducible
transmembrane protein that restricts the release of nas-
cent viral particles from infected cells by tethering
them to the PM [266,267] reviewed in [268,269]. HIV-1
counteracts tetherin activity through Vpu (HIV-1)
[266,267] which enhances ESCRT-dependent sorting for
lysosomal degradation [270,271], whereas SIV Nef [272],
and the HIV-2 Env ectodomain [273] counteract tetherin
by intracellular sequestration through internalization
motifs. One recent study reported that a Nef-deleted SIV
strain acquired compensatory changes within the gp41-
CT that restored resistance to rhesus tetherin through dir-
ect gp41-CT/tetherin interaction that sequestered tetherin
[272]. The alterations of the SIV gp41-CT involved a
tyrosine-based internalization motif similar to the HIV-2
gp41-CT [272], underlining the importance of countering
tetherin and of Env trafficking for lentiviral replication. No
such evolution has been reported for HIV-1.
Open questions
Numerous cellular proteins have been described to inter-
act with the gp41-CT. Some of these proteins and inter-
actions have been studied in detail, particularly those
involved in Env internalization and trafficking through
the TGN. However, in many cases, the role or the mech-
anisms of these interactions have not been documented.
In some cases, the results and interpretations are con-
troversial, and raise questions about whether the pro-
teins are really involved in the viral replication cycle as
active partners, or whether they are passively incorpo-
rated into the assembly platform, where they make onlya limited if any contribution to viral replication. Differ-
ent studies have been performed using different cell
types and cell lines, each with their specific characteris-
tics. Thus, there are issues about whether they reflect
phenotypes of cell types relevant to the HIV replication
cycle in vivo. Similarly, do these experimental models re-
flect the context of cell-to-cell transmission where the
vicinity of cells and cell contacts are determinant param-
eters of viral infection and transmission? Some motifs
involved in Env internalization and trafficking, as well as
those involved in interaction with lipid rafts and in en-
hanced viral gene expression, are highly conserved
across subtypes; others seems to display non-negligible
sequence variation. It would be useful to assess whether
such apparent tolerance identifies interactions that are less
vital for viral replication, or whether the virus has acquired
other compensatory polymorphisms to override decreased
efficiency of that particular interaction.
Conclusions
Initially considered to be inessential for the HIV rep-
lication cycle, the gp41-CT has now been demon-
strated to be a pleiotropic domain: it is required for
viral infectivity by ensuring Env incorporation into
the virion on one hand, and contributing to en-
hanced viral replication in target cells through many
still incompletely understood interactions on the
other. Work on the gp41-CT has revealed that lentiviral
assembly relies on finely coordinated interactions between
diverse viral components subverting cell trafficking and
activation factors. The virus thereby optimizes the infec-
tious capacity of the neo-synthesized particle, prevents im-
mune responses and preserves the virus-producing host
cell until viral release. The uncontrolled release of imma-
ture virions would not only hinder viral propagation and
be deleterious to the long-term maintenance of viral infec-
tion, but would also provoke a series of bystander effects,
including Env-induced apoptosis, Env-mediated disruptive
effects, and sensitivity to humoral immune responses.
The Env expressed on the surface of infected cells and of
virions is one of the most powerful escape mechanisms de-
veloped by HIV. Its extreme variability, dense glycosylation
and its very efficient cell-to-cell spreading capacity ensure
extremely effective virus shielding. This shielding is further
strengthened by the only weak expression of Env at the
surface of infected cells and of virions, resulting from its
late expression during the viral replication cycle, intense
cycling and down-regulation through the TGN. Interfer-
ence with cellular trafficking factors further contributes to
viral masking. These latter functions are all fulfilled by the
gp41-CT. Indeed, despite some sequence divergence be-
tween subtypes, structural motifs and some sequences mo-
tifs in the gp41-CT are strongly conserved. In particular,
elements involved in Env trafficking from the plasma
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are conserved, underscoring their importance for viral rep-
lication and propagation. Other motifs involved in protein-
protein interactions are not conserved providing evidence
of subtype-related specificities. Such differences between
subtypes have been poorly studied to date. The fine bal-
ance between sequence variability and highly controlled
protein trafficking and dynamics allows the virus to
optimize viral infectivity and viral propagation. The viral
determinants that are poorly tolerant to polymorphic vari-
ation may well be interesting subjects for investigations to
elucidate the subtle control of viral assembly, budding and
release. Such work may lead to the identification of interac-
tions that are possible targets for new antiviral strategies.
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